Amylyx Pharmaceuticals Inc Total Liabilities
Amylyx Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has total liabilities worth $25.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Amylyx Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Amylyx Pharmaceuticals Inc (2019–2025)
Total liabilities of Amylyx Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Amylyx Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Amylyx Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aris Mining Corporation
TO:ARIS
|
Canada | CA$1.06 Billion |
|
WNS Holdings Ltd
NYSE:WNS
|
USA | $771.00 Million |
|
FPT Corp
VN:FPT
|
Vietnam | ₫28.46 Trillion |
|
Genworth Financial Inc
NYSE:GNW
|
USA | $77.60 Billion |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
China | CN¥9.08 Billion |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
China | CN¥4.61 Billion |
|
China Hainan Rubber Industry Group Co Ltd
SHG:601118
|
China | CN¥24.13 Billion |
|
Old Mutual Ltd
JSE:OMU
|
South Africa | ZAC1.19 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Amylyx Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Amylyx Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Amylyx Pharmaceuticals Inc Total Liabilities Ratios Explained
Amylyx Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amylyx Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Amylyx Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $27.39 Million | -5.14% |
| 2024-12-31 | $28.87 Million | -65.64% |
| 2023-12-31 | $84.02 Million | +65.25% |
| 2022-12-31 | $50.85 Million | -80.20% |
| 2021-12-31 | $256.78 Million | +217.69% |
| 2020-12-31 | $80.83 Million | +182.85% |
| 2019-12-31 | $28.58 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more